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 First real time immunoassay within a free standing macroporous alumina membrane. 
 Targeted delivering of analytes to bioreceptors immobilized on pore walls 
 Fast sensing response times and small sample volumes (< 100 µl). 
 A novel two step procedure for a functional coating of DMA and NAS on AAO.  
 The first time poly(DMA-NAS) coating has immobilized allergens on a porous surface. 
Research Highlights
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Abstract: Through the presentation of analytical data from bioassay experiments, 15 
measured by polarimetry, we demonstrate for the first time a real time 16 
immunoassay within a free standing macroporous alumina membrane. The 17 
200 nm nominal pore diameter of the membrane enables flow-through, thereby 18 
providing an ideal fluidic platform for the targeted delivery of analytes to 19 
bioreceptors immobilized on the pore walls, enabling fast sensing response times 20 
and the use of small sample volumes (< 100 µl). For the immunoassay, the pore 21 
walls were first coated with the functional copolymer, copoly(DMA-NAS) using a 22 
novel coupling process, before immobilization of the allergen protein, β-23 
lactoglobulin, by spotting. The immuno-assay then proceeded with the binding of 24 
the primary and secondary antibody cognates, rabbit anti-β-lactoglobulin and anti-25 
rabbit IgG respectively. Through the use of streptavidin coated quantum dots as 26 
refractive index signal enhancers, a noise floor for individual measurements of 3.7 27 
ng/ml (25pM) was obtained, with an overall statistical, or formal assay LOD of 33.7 28 
ng/mL (225pM), for total assay time below one hour.  29 
Index Terms: Porous alumina; Form birefringence; Polarimetry; Optical biosensing; copolymer; quantum dots. 30 
1. Introduction  31 
Due to an increasing demand for rapid, reliable and economical near patient or field testing, over 32 
the last few decades there has been a strong trend toward in-vitro point of care (PoC) testing in 33 
clinical diagnosis, food safety, environmental monitoring, safety and security [1, 2]. Significant 34 
segments of PoC testing are based on bioassays where extremely low concentrations of markers 35 
(infectious agents, pesticides, cardiac markers, allergens etc.) need to be identified and 36 
distinguished from other matter within small volumes of complex matrices (e.g. whole blood, 37 
sputum swabs, faeces, cell lysate…). To meet these needs, PoC in-vitro diagnostic devices are 38 
required to provide a fast, sensitive and selective analysis of assays, ideally a simultaneous 39 
analysis of multiple assays, and therefore new approaches being explored are often based on 40 
highly integrated sensors within a Lab on Chip format [3]. Furthermore, for low cost and practical 41 
application by non-technical users, optimal designs negate the need for lengthy off-chip sample 42 
preparation.  43 
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At the core of these devices is the biosensor [4] and those based on optical interrogation offer 1 
important advantages such as: 1) non-invasive, safe and multi-dimensional (intensity, wavelength, 2 
phase, polarization) detection; 2) well-established tools from communication and Micro-Nano 3 
technologies (MNT) industries (lasers, detectors, waveguides) and 3) optical frequencies that 4 
coincide with a wide range of physical properties of bio-related materials.  5 
Many optical biosensors are based on refractive index (RI) sensing, where the effective refractive 6 
index of the surface of an optical structure is modified by the presence of a target analyte [5]. For 7 
the development of photonic biosensors, nanostructured materials like porous silicon (PSi) or 8 
porous alumina (AAO) have gained special attention, as they have higher surface areas than 9 
planar biosensors for capturing analytes and thus permit lower detection limits [6]. To date, several 10 
label-free photonic biosensors have been successfully developed on both PSi [7, 8] and AAO [9, 11 
10] porous membranes, using reflectometric interference spectroscopy (RIfS). However, this 12 
approach produces slow responses and long sensing times, due to the narrow (<100nm) closed 13 
end pores of the membranes used, resulting in analyte delivery being mainly governed by the 14 
stationary flux produced by electrostatic interactions. The problem of analyte delivery has been 15 
obviated in a fluorescent flow-through assay using a fibrous filter as an improved method for 16 
protein capture [11], however this was as an ex-situ end point assay which after the analyte was 17 
bound required the substrate to be dried and transferred to a reader for measurement under index 18 
matched liquid. In a recent approach using optical polarimetry [12], we demonstrated that free 19 
standing macroporous AAO membranes with 200nm diameter pores when functionalized with an 20 
epoxysilane allow analytes to flow-through them. Due to the pore size, the analyte molecules flow-21 
through no more than 100 nm from the assay surface (the pore wall), breaking the mass transport 22 
limitations and so effectively targeting their delivery, for real-time biosensing responses, an 23 
approach which has also been proposed elsewhere with similar porous optical structures [13, 14].  24 
Here, we report on the use of this approach for immunosensing, by coating the membrane with a 25 
functional copolymer, copoly(DMA-NAS), through a novel procedure that has demonstrated less 26 
non-specific binding, and therefore greater selectivity, and more stability over time for immobilized 27 
allergens than epoxysilane [15]. In this paper, we first detail the procedure for immobilizing the 28 
bioreceptors inside the pores of the alumina membrane, including the novel process for coating the 29 
pores with the copolymer. After demonstrating the stability of the immobilized allergens, we show a 30 
5 times signal enhancement through the use of streptavidin coated quantum dots (SA-QDs) 31 
compared to the secondary antibody used. Finally, we show the concentration performance of the 32 
immunoassay by using solutions of the first antibody at different concentrations, followed by a fixed 33 
concentration of the secondary antibody and streptavidin coated quantum dots.  34 
2. Material and methods 35 
2.1 Material 36 
The free-standing macroporous alumina membranes were purchased from Whatman (Anodisc™ 37 
membranes, 13 mm diameter, 200 nm nominal pore diameter, 60 μm thickness and 0.5 porosity) 38 
and several were characterised morphologically by SEM to verify the approximate pore dimensions. 39 
PBS (Phosphate buffered saline) tablets, Tween 20, toluene, dimethylformamide (DMF) N,N-40 
dimethylacrylamide (DMA), [3-(methacryloyl-oxy)propyl]trimethoxysilane (MAPS), tetrahydrofuran 41 
(THF), azoisobutyonitrile (AIBN) and absolute ethanol, were acquired from Sigma-Aldrich (St. Louis, 42 
MO, USA). N-acryloyloxysuccinimide (NAS) was synthesized as reported elsewhere [16].  43 
The primary antibody employed rabbit anti-β-lactoglobulin, was purchased from Bethyl 44 
Laboratories (Montgomery, TX, USA). Antigen protein β-lactoglobulin B, the secondary antibody, 45 
biotinylated anti-rabbit IgG, and BSA (Bovine serum albumin), were purchased from Aldrich (St. 46 
Louis, MO, USA). Strepavidin conjugated CdSe quantum dots (Qdot® 800 Streptavidin Conjugate) 47 
were supplied by Invitrogen (Life technologies, NY, USA). All buffers were filtered through 0.2um 48 
filters before use. 49 
Page 4 of 14
Ac
ce
pte
d M
an
us
cri
pt
 1 
2.2 Bioreceptor immobilization 2 
One of the key factors for the development of optical biosensors for point-of-care diagnostic 3 
devices is the immobilization of the bioreceptors on the sensor surface in a way that retains a high 4 
degree of activity and low levels of non-specific binding. A polymeric coating introduced by Pirri and 5 
co-workers in 2004 [17] was shown to possess favorable characteristics for performing an optimal 6 
microarray analysis. This coating is obtained by adsorption on solid surfaces of a diluted aqueous 7 
solution containing a co-polymer, which provides a stable and hydrophilic film. This polymer, 8 
poly(DMA-NAS-MAPS) is obtained by random radical polymerization of three monomers: N,N-9 
dimethylacrylamide (DMA), which self-adsorbs on glass by weak, non-covalent interactions with 10 
silanol groups, 3-(trimethoxysilyl)propyl methacrylate (MAPS), which stabilizes these interactions 11 
by the formation of stable, covalent bonds and N-acryloyloxysuccinimide (NAS), which represents 12 
the chemically reactive groups with the aim to bind biomolecules on the surface. Thanks to its 13 
monomer composition this copolymer provides a low fluorescence background for surfaces and a 14 
highly selective binding chemistry whilst retaining the native configuration of immobilized probes. 15 
This polymer has been previously demonstrated to immobilize allergens on different materials such 16 
as glass, nitrocellulose and silicon slides [18] and more recently on a SiOxNy Dual Polarization 17 
Interferometry chip [15] allowing the efficient measurement of their interactions with allergen-18 
specific Immunoglobulin E (IgEs) in the complex matrix of serum, proving its suitability as a non-19 
fouling coating and that it is robust to allergen storage.   20 
For this work it was not possible to coat the surface with poly(DMA-NAS-MAPS) using the usual dip 21 
and rinse method, due to the instability of AAO towards some of the reagents used in the 22 
procedure, therefore, a functional coating of DMA and NAS was obtained via a novel two step 23 
procedure involving modification of the surface with MAPS followed by the grafting of poly(DMA-24 
NAS) formed by in situ radical polymerization. This coating was used for the first time to immobilize 25 
allergen proteins on a porous surface.  26 
 27 
Figure 1. Scheme of the grafting process of poly(DMA-NAS) onto an AAO membrane 28 
silanized with MAPS that bears an allyl group which allows polymerization with DMA and 29 
NAS  30 
 31 
2.2.1 Pore surface coating 32 
Before the pore surfaces were coated, the membranes were cleaned with an oxygen plasma for 10 33 
minutes in a Harrick Plasma cleaner (Ithaca, NY, USA) and then immersed in a solution of MAPS 34 
in toluene (10% v/v). A vacuum was applied for 10 minutes in order to assure that the pores were 35 
completely filled with this solution, before the reactor was sealed and left overnight at room 36 
temperature. After silanization, the membranes were first washed on a Buchner funnel, under 37 
vacuum with toluene and then with THF and finally cured under vacuum at 80°C for 30 minutes. 38 
Thereafter, a 20 mL solution of 10% DMA and NAS in DMF (molar ratio 90-10; 1.85 mL, 17.95 mM 39 
and 340 mg, 2.01 mM respectively) was prepared. The silanized membranes were then immersed 40 
in this solution and an argon purge was used to remove oxygen from the solution for 15 minutes. 41 
AIBN (6.5 mg, 2 mM) was then added and a vacuum applied for 10 minutes to assure that the 42 
pores were completely filled with the degassed monomer solution and then the reactor was sealed 43 
and heated with a silicon bath, at 65°C overnight. Finally, the membranes were washed on a 44 
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Buchner funnel, under vacuum, first with DMF and then with THF, before being dried under 1 
vacuum at room temperature.  2 
 3 
2.2.2 Allergen immobilization 4 
The allergen -lactoglobulin was spotted onto the coated membranes using a piezoelectric spotter 5 
(Scienion SciFlexArrayer S5). Several droplets of a solution of -lactoglobulin (1mg/mL in PBS) 6 
were spotted in the central area of the membranes so as to form a square of 5x5 mm. Membranes 7 
were layered on nitrocellulose slides wetted with 10 µL of the same antigen solution, so to assure 8 
complete filling of the pores by capillary action. The spotted membranes were then left overnight in 9 
a moisture chamber before being rinsed with PBS, on a Buchner funnel, and then treated with a 10 
solution of BSA (0.1 mg/mL) to block any remaining active sites of the coating. 11 
 12 
2.3 Membrane transfer to supports 13 
After having immobilized the bioreceptors on the functionalized free-standing membranes, in order 14 
to conduct flow-through sensing experiments, the circular membranes were first transferred onto 15 
mechanical support chips (Figure 2). The support chips chosen were 15 by 15 mm pieces of single 16 
side polished silicon wafer, 500 μm thick, due to their stability in an aqueous environment as well 17 
as the flat interface they provide for a good mechanical contact between them and the membranes. 18 
The support chips had a 750 μm diameter opening in the centre which was made using a CO2 laser, 19 
and the edges were chamfered on the reverse side in order to allow the laser light to readily pass 20 
through the hole without being occluded by the walls of the support chip. A 1 μm thick layer of 21 
PMMA (Poly(methyl methacrylate)) resist was used as the adhesion layer between the alumina 22 
membranes and the silicon supports. Support mounted membranes were then stored in a 23 
desiccator at 4 °C until they were used in the biosensing experiments. This set-up forms a 750um 24 
diameter active spot area and is compatible with a multispot format which would allow multiplexed 25 
assays. Smaller spots are also be possible as the measurement sensitivity is in principle not spot 26 
size dependent. 27 
15 mm
Silicon 
support
Macroporous
AAO membrane
750 μm 
 28 
Figure 2. Picture of a free standing membrane mounted on a silicon support. 29 
 30 
2.4 Readout platform 31 
The readout platform (Figure 3a) used a polarimetric setup [19] to interrogate the changes in the 32 
optical anisotropy of the macroporous free-standing membranes, the sensing mechanism for the 33 
bioassay. Analyte molecules within the pores modify the birefringence which is detected within the 34 
setup as a change of phase retardation between the components of light polarized along the main 35 
axis directions. Briefly the setup is: the output light from a 980 nm laser diode is first collimated and 36 
then directed to a linear polarizer with the resulting linearly polarized light then entering a 37 
photoelastic modulator (PEM; Hinds Instruments PEM-100). The modulated light exiting the PEM is 38 
then incident at 45º to the planar surface of the alumina membrane, which is mounted on the 39 
support chip within a flow-cell. The light exiting the membrane, after passing a second polarizer, is 40 
detected by a photodiode which is connected to a lock-in amplifier (SR-830). The lock-in amplifier 41 
demodulates the detected signal extracting the amplitudes of its first and second harmonics, which 42 
are related to the phase retardation.  43 
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The fluidic setup used within the readout platform allows the analytes to be pumped through the 1 
flow cell encased and mechanically supported membrane by use of a pressure controller 2 
connected to a syringe where the running buffer is stored (Figure 3b). Before filling with liquid, the 3 
system is purged with CO2 for 5 minutes to ensure complete filling and to reduce the incidence of 4 
bubbles. The purging consists of the CO2 displacing the air in the system and any that is not 5 
displaced on filling with solution is then dissolved in the water or buffer.  6 
 7 
Figure 3. (a) Layout of the optical polarimetric readout platform used for measuring the phase 8 
retardation within the membranes. (b) Scheme of fluidic setup integrated within a flow-cell where 9 
the mounted membrane is placed and whose inlet port is connected to a pressure controller 10 
providing a constant pressure flow. 11 
 12 
2.5 Immunosensing experiments 13 
After mounting a membrane with immobilized allergen into the flow-cell and purging with CO2, a 14 
running buffer of PBS-T (PBS, 0.02% (v/v) Tween 20) was introduced for 15 minutes before the 15 
behaviour of the immobilized allergen was tested by injecting its cognate antibody rabbit anti-β-16 
lactoglobulin. The membrane was then rinsed again with the running buffer and the secondary 17 
antibody anti-rabbit-IgG (biotinylated) was then introduced into the system followed by streptavidin 18 
conjugated quantum dots (SQ-QD) as signal enhancers, which increased the sensitivity for low 19 
concentrations of the primary antibody. A schematic representation of this bioassay is depicted in 20 
Figure 4.  21 
 22 
Figure 4. The immunoassay carried out in a macroporous alumina membrane. β-lactoglobulin 23 
protein was used as the immobilized antigen for the detection of rabbit anti-β-lactoglobulin. 24 
Biotinylated secondary antibody (anti-rabbit-IgG) and streptavidin coated CdSe quantum dots 25 
were used to increase the signal produced by the primary antibody. 26 
 27 
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3. Results and discussion 1 
 2 
3.1. Characterization of AAO membranes 3 
The membranes were analyzed by FT-IR after each step of the coating process, to confirm that the 4 
chemical modification was taking place as intended. The signals from uncoated membranes (blank 5 
samples) were subtracted from the spectra of modified membranes (using Spectra Manager 6 
software 1.52 from Jasco, MD, USA) so as to highlight the peaks corresponding to the coating 7 
reagents. The subsequent FT-IR spectra of the polymer coated membranes, Figure 5, show a peak 8 
around 1740 cm
-1
 corresponding to the stretching of carbonyl group of MAPS which increases 9 
when NAS is added onto the surface. On coated membranes, as well as the NAS peak, it is 10 
possible to observe a peak at 1640 cm
-1
 which corresponds to the stretching of the DMA carbonyl 11 
group. For comparison, an FT-IR (poly(DMA-NAS-MAPS) was also recorded, so as to confirm the 12 
presence of the coating on the membrane. 13 
 14 
Figure 5. FT-IR analysis of a functional polymer coated membrane. Peaks corresponding to DMA 15 
and NAS carbonyl moities are easily observed when compared to an uncoated membrane. 16 
 17 
3.3 Immunosensing results 18 
The activity of the immobilized allergens was tested by running the immunoassay explained in 19 
Section 2.5. Figure 6 shows the measured phase retardation when concentrations of 1 μg/mL (6.7 20 
nM) are used for the first and secondary antibody and a concentration of 2.5 nM is used for the SA-21 
QD. After placing the alumina membrane in the flow-cell and prior to the antibody injections, the 22 
baseline obtained during the buffer rinse showed good stability which demonstrated that the 23 
antigen is stably immobilized on the polymer coated surface. After recording a stable baseline 24 
during six minutes we then injected the first antibody rabbit anti-β-lactoglobulin for a period of 10 25 
minutes. Following a six minutes rinse with the running buffer the secondary antibody anti-rabbit 26 
IgG was then injected for 10 minutes. As the secondary antibody is polyclonal, a larger response is 27 
observed for this, compared to the binding of the initial primary antibody. After further rinsing, the 28 
SA-QDs were added as a signal enhancer at a concentration of 2.5 nM, which was sufficient to 29 
saturate the captured secondary antibodies. Due to the size of the SA-QDs an enhancement of 5 30 
times is observed in the signal over the response produced by the secondary antibody.  31 
After this experiment a series of experiments was run using 12 different membranes with the same 32 
immunoassay where the concentration of the first antibody was varied between 5 and 1000 ng/mL 33 
in order to estimate the detection limit of the system. Figure 7 (a) shows the overlaid response 34 
obtained for the different membranes.  35 
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 1 
Figure 6. A sensorgram showing the signal response due to the binding of the first and secondary 2 
antibodies, followed by the enhancement produced by the SA-QD. 3 
 4 
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Figure 7. (a) An overlay of the signal responses produced by the SA-QD when the 6 
concentration of the first antibody is increased from 5 ng/mL to 1000 ng/mL. (b) Phase 7 
retardation change upon injection of 2.5 nM SA-QD over biosensing experiments using a 8 
range of primary antibody concentrations (5-1000 ng/mL). The fitted line corresponds to 9 
a 1:1 binding model of KD 228 ng/mL and Rmax of 7.7 mrad. 10 
 11 
In Figure 7 (b), we present the phase retardation change produced by the signal enhancement 12 
quantum dots as a function of the concentration of the first antibody. The limit of detection of the 13 
system was calculated according to the formula given in [20], which defines the analytical limit of 14 
detection as the analyte concentration that can reliably be distinguished from the noise: 15 
_ _1.645 low concentration sampleLoD LoB SD     (1)  16 
where SDlow_concentration_sample corresponds to the standard deviation obtained from a series of 17 
samples at low concentration and LoB is the limit of blank defined as the highest analyte 18 
concentration value expected to be obtained for a sample containing no analytes. LoB is equal to:  19 
1.645blank blankLoB mean SD       (2)  20 
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Where meanblank corresponds to the mean value obtained from a series of blank samples and SD 1 
corresponds to the standard deviation of the samples.  2 
In our case, using β-lactoglobulin as the immobilized antigen, the limit of detection of our system 3 
was 33.7ng/ml. This value is chiefly limited by the reproducibility of the mechanical setup rather 4 
than the measurement signal noise level, which would establish a limit an order of magnitude lower, 5 
at 3.7 ng/mL. For application in clinical allergy diagnostics, a measurement range of 0.84-240 ng/ml 6 
(0.35-100 kU/L) is required by clinicians [21], and thus the presented proof-of-concept system 7 
already shows relevant performance for this application. With improvements in the mechanical 8 
design and further assay optimization, we expect to improve the detection limit to cover the full 9 
range. 10 
Compared to previous work employing porous membranes in a flow-over configuration, the flow-11 
through configuration applied here enables more efficient convective delivery of analytes to the 12 
immobilized recognition molecules. This results in a short total assay time of below 60 minutes for 13 
a sandwich assay employing both a secondary and tertiary binding, compared to flow-over assay 14 
times of 5 hours for a two-step assay in [8]. Furthermore, in a flow-through configuration the entire 15 
sample passes through the membrane in close proximity to the immobilized recognition molecules, 16 
and hence the sample utilization is greatly improved. For example, the total analyte containing 17 
sample volume consumed during the 10 minute injection in this work was 1 mL, while in [8] a total 18 
volume of 50 mL was consumed (100 minute injection at a flow rate of 0.5 mL/min). In terms of 19 
analyte mass consumed, the contrast is even more stark, i.e. 1 µg (1 mL of 1 µg/mL Anti-β-20 
lactoglobulin solution) in flow-through, compared to 5 mg (50 mL of a 0.1 mg/mL IgG solution) in 21 
flow-over [8]. This difference is particularly important for analysis of small and costly samples, such 22 
as in neonatal diagnostics and drug development, respectively. 23 
 24 
4. Conclusions 25 
We have demonstrated for the first time a real time immunoassay within a free standing flow-26 
through macroporous alumina filter membrane, which provides a route towards rapid and low cost 27 
biosensing.  28 
Both the stability and the functionality of the coating and spotting procedure were evaluated by 29 
injecting inside the pores the antibodies rabbit anti-β-lactoglobulin and anti-rabbit-IgG. The 30 
response produced by the binding between the allergen protein and its cognate antibodies was 31 
acquired in real-time, by using an optical polarimetric readout platform to measure the anisotropy 32 
change of the macroporous alumina membrane.  33 
Finally, the use of streptavidin conjugated CdSe quantum dots was investigated as refractive index 34 
signal enhancers obtaining five-fold signal amplification compared with the signal produced by the 35 
secondary antibody alone. Using this signal amplifier a noise floor for individual measurements of 36 
3.7ng/ml (25pM) was obtained, with an overall statistical, or formal assay LOD of 33.7 ng/mL 37 
(225pM), for total assay times of under one hour. 38 
 39 
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